ArticleCancer biomarkers : section A of Disease markers2019
Clinical significance of the expression of long non-coding RNA PVT1 in glioma.
Article in Cancer biomarkers : section A of Disease markers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 16 citations in OpenAlex.
- LncRNA-PVT1 was identified as a key regulator for TMZ resistance and STAT-related pathway in glioma.BMC cancer · 2023Article
- Targeting long non-coding RNA PVT1/TGF-β/Smad by p53 prevents glioma progression.Cancer biology & therapy · 2022Article
- Depleting SOX2 improves ischemic stroke via lncRNA PVT1/microRNA-24-3p/STAT3 axis.Molecular medicine (Cambridge, Mass.) · 2021Article
- 8q24.21 Locus: A Paradigm to Link Non-Coding RNAs, Genome Polymorphisms and Cancer.International journal of molecular sciences · 2021Review
- Long Non-Coding RNAs in Diagnosis, Treatment, Prognosis, and Progression of Glioma: A State-of-the-Art Review.Frontiers in oncology · 2021Review
- Comprehensive Analysis of REST/NRSF Gene in Glioma and Its ceRNA Network Identification.Frontiers in medicine · 2021Article
- Upregulation of lncRNA plasmacytoma variant translocation 1 predicts poor prognosis in patients with muscle-invasive bladder cancer.Medicine · 2020Observational
- Competing endogenous RNA network analysis reveals potential long non-coding RNAs as predictive biomarkers of gastric cancer.Oncology letters · 2020Article
- Long Intergenic Non-Protein Coding RNA 1094 Promotes Initiation and Progression of Glioblastoma by Promoting microRNA-577-Regulated Stabilization of Brain-Derived Neurotrophic Factor.Cancer management and research · 2020Article
- Long Non-Coding RNA PVT1 Regulates BAMBI To Promote Tumor Progression In Non-Small Cell Lung Cancer By Sponging miR-17-5p.OncoTargets and therapy · 2020Article
- PVT1 Promotes Cancer Progression via MicroRNAs.Frontiers in oncology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlioma is the most common primary malignant tumor in the nervous system.
objectiveTo investigate the expression of long non-coding RNA Pvt1 oncogene (PVT1) in glioma and its clinical significance.
methodsThe expression levels of PVT1 were determined in 59 glioma and 10 normal tissue samples using qRT-PCR. The patients were divided into high and low expression groups and analyzed for their relationship with clinicopathological factors and the survival time using the Kaplan-Meier method.
resultsThe expression levels of PVT1 were significantly higher in glioma tissues than in normal tissues (p< 0.01) and higher in high grade (III-IV) than in low grade (I-II) tumors (p< 0.01). Analysis showed that the PVT1 level was closely related to glioma grade (p< 0.01), but not to age, gender, Karnofsky performance status (KPS) and tumor size (p> 0.05). Receiver operator characteristic curve analysis showed an area under the curve of 0.835. Log-rank test showed that the prognosis of high PVT1 group was poorer than that of low PVT1 group (p< 0.01).
conclusionsPVT1 is highly expressed in gliomas and its level is positively related to WHO glioma grade and prognosis of gliomas. Therefore, it may be explored as a new molecular marker for predicting malignancy and prognosis of gliomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.